Windward Bio secured $165 million in financing to fund clinical trials for its respiratory antibody pipeline, including a lead long-acting program aimed at asthma, COPD and related indications. The company also advanced a second long-acting antibody program intended for potential use across respiratory and dermatological settings. The funding positions Windward to expand clinical evaluation of next-generation biologics designed for dosing convenience versus existing antibody therapies. Industry watchers will focus on how the programs translate long-acting pharmacology into efficacy and durability across chronic inflammatory targets. Windward’s approach—deploying long-acting antibodies across more than one disease area—underscores how respiratory immunology remains a high-competition, execution-driven segment where differentiation depends on dosing intervals and measurable patient benefit. With the capital secured, the near-term newsflow will likely center on trial start timelines, enrollment momentum, and early clinical readouts that could validate the dosing strategy.